Emerging Diagnostic Firm Says It Got Mixed Messages From FDA
This article was originally published in The Gray Sheet
Executive Summary
InterGenetics, an early stage firm specializing in genetic tests and RNA-based treatments, complains that it faces an uncertain future after getting conflicting feedback from FDA about marketing its cancer diagnostic